5 Result(s)
-
Article
IL-2 in the therapy of melanoma and other malignancies
IL-2 as a single agent has been approved for use in both renal cancer and melanoma, and it has achieved widespread use in these malignancies for selected patients with metastatic disease. For these diseases, a...
-
Article
Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium
Oblimersen is an 18-base oligodeoxynucleotide encoding antisense to the gene for bcl-2, an anti-apoptotic protein that is upregulated in renal and other cancers. This study was designed to evaluate the combina...
-
Article
Kidney cancer: The cytokine working group experience (1986–2001)
The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regar...
-
Article
Kidney cancer: The cytokine working group experience (1986–2001)
The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regar...
-
Article
Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial
A phase II trial of menadione (2.5 g/m2 as a continuous intravenous infusion over 48 h) followed by mitomycin C (10–20 mg/m2 i.v. bolus) administered every 4–6 weeks was performed in 43 patients with advanced gas...
